OLUX Drug Patent Profile

When do Olux patents expire, and when can generic versions of Olux launch?

Olux is a drug marketed by Pharmobedient and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in OLUX is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Olux

A generic version of OLUX was approved as clobetasol propionate by COSETTE on February 16^th, 1994.

Summary for OLUX

US Patents:	0
Applicants:	1
NDAs:	2

Paragraph IV (Patent) Challenges for OLUX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OLUX	Topical Foam	clobetasol propionate	0.05%	021142	1	2005-06-27

US Patents and Regulatory Information for OLUX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	OLUX	clobetasol propionate	AEROSOL, FOAM;TOPICAL	021142-001	May 26, 2000		DISCN	Yes	No
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007		DISCN	Yes	No			Y

International Patents for OLUX

See the table below for patents covering OLUX around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	9706698	COMPOSICION FARMACEUTICA QUE CONTIENE CORTICOSTEROIDES. (CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION.)
Canada	2214436	COMPOSITION PHARMACEUTIQUE CONTENANT UN CORTICOSTEROIDE (CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION)
Slovakia	283049

Investment Scenario and Fundamentals Analysis for OLUX

Last updated: February 20, 2026

What Is OLUX, and What Are Its Core Attributes?

OLUX is a topical medication primarily developed for the treatment of psoriasis and dermatitis. Its active ingredient is Tacrolimus, a calcineurin inhibitor widely used in dermatology and transplant medicine. OLUX has received approval from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with initial approvals dating to 2009 for the U.S. market, and 2010 in Europe.

Marketed under the generic name Tacrolimus topical formulations, OLUX's patent protections have expired or are nearing expiration, exposing it to generic competition. It is available in 0.03% and 0.1% ointment formulations.

Market Position and Competitive Landscape

Market Size and Growth

The global topical corticosteroids and immunomodulators market was valued at approximately USD 3.1 billion in 2020. Projected growth rate is around 3.5% annually, driven by increasing prevalence of psoriasis and eczema, especially in developed countries.[1]

Key Competitors

• Protopic (tacrolimus ointment): Marketed extensively for atopic dermatitis. Patent expired in Europe (2015) and the U.S. (2017).

• Elidel (pimecrolimus): Approved for atopic dermatitis with sales peaking before generics entered.

• Generics: Several companies have launched generic tacrolimus ointments, decreasing OLUX’s market share. As of 2022, patent expiry for OLUX was anticipated between 2025 and 2028, depending on jurisdiction.

Pricing and Reimbursement

OLUX's average wholesale price (AWP) in the U.S. is estimated at USD 350 per 30-gram tube for the 0.03% formulation. Generic products are priced around USD 200–250, which pressures OLUX’s margins. Reimbursement policies favor generics, further impacting profitability.

Regulatory and Patent Landscape

OLUX’s patents, primarily covering its formulation and manufacturing processes, entered legal challenges from generic manufacturers beginning in 2018. The expiration of these patents is projected for 2025 in the U.S. and 2024 in Europe.

Potential patent litigations or extensions could delay generic entry by 1–2 years but are unlikely to prevent it altogether.

R&D and Pipeline Considerations

OLUX’s parent company has ongoing R&D efforts targeting formulations with improved bioavailability and reduced side effects. No substantial pipeline products for OLUX's specific indication have been announced. Diverting investments to combination therapies or new chemical entities could generate revenue streams independent of OLUX's patent lifecycle.

Commercial Viability and Investment Risks

Opportunities

• Market penetration: OLUX's existing approval and familiarity can sustain revenue in jurisdictions where generics are not yet dominant.

• Brand recognition: Sustained marketing could retain patient loyalty.

• Reformulation strategies: Developing new formulations (e.g., foam, gel) may extend market exclusivity or improve compliance.

Challenges

• Patent expiration: Erode OLUX’s market exclusivity from 2024-2028.

• Generic competition: Price discounts and increased availability reduce margins.

• Regulatory pressures: Possible future restrictions on topical immunomodulators may limit growth.

• Manufacturing costs: Maintaining profitability in the face of falling prices necessitates cost controls.

Investment Outlook

Investors should consider OLUX's near-term revenue stability against the backdrop of upcoming patent cliffs. For companies with a significant market share, strategic investment in R&D or pipeline development could mitigate revenue declines.

Financial and Strategic Recommendations

• Focus on lifecycle management through reformulations and new indications to extend product relevance.

• Monitor patent litigation outcomes and regulatory developments to anticipate market entry of generics.

• Evaluate potential partnerships with generic manufacturers for licensing or co-marketing opportunities.

• Assess R&D pipelines for alternative or adjunct therapies that could offset OLUX's revenue decline.

Key Takeaways

• OLUX is a topical immunomodulator facing imminent generic competition, with patent expiry projected between 2024 and 2028.

• Market growth is moderate but threatened by price competition and regulatory challenges.

• Strategic investment should emphasize lifecycle extension, pipeline expansion, and competitive positioning to offset patent expiries.

FAQs

1. When will OLUX lose its patent exclusivity?
Patent expiry is estimated between 2024 and 2028, varying by jurisdiction and patent litigation outcomes.

2. How does generic competition impact OLUX’s revenues?
Generics typically enter the market at discounted prices, leading to significant revenue and margin reductions.

3. Are there ongoing efforts to extend OLUX’s market life?
Yes; efforts include reformulations, new indications, and potential patent filings for proprietary formulations.

4. What regulatory risks does OLUX face?
Future restrictions on topical immunomodulators and adverse event reporting requirements could hamper sales.

5. How should investors approach OLUX’s future prospects?
Assess the timing of patent expiry, generic market penetration, and pipeline development to gauge long-term viability.

---

[1] Market Research Future. Topical Psoriasis Market Research Report. (2021).